Mavencorp Capital is proud to share that Bioma, our portfolio company operating at the frontier of diagnostics, health, and wellbeing, has signed an exclusive pharmaceutical distribution partnership covering GLP-1, NAD+, and Vitamin drop therapies.
The agreement gives Bioma preferential commercial rates across one of the fastest-growing segments in metabolic health and provides a scalable platform for pharmaceutical distribution across the UK and selected international territories. It also extends Bioma's access to pharmaceutical licensing infrastructure through its partnership with Medipoint, with discussions already underway on wider GLP-1 distribution opportunities, including engagement with Boots UK.
This builds directly on Bioma's existing clinical infrastructure and its growing reputation as a real-world health technology validation site, a position it has been deliberately building through partnerships across the UK, Asia, and the GCC.
"Bioma is positioning itself at the front of health, medicine and wellbeing treatments and continues to prove it can move quickly and commercially in a market that is evolving just as fast."
— Nivaan Goyal, Founder and Managing Principal, Mavencorp Capital
Bioma is actively building out its distribution network, seeking introductions to pharmaceutical wholesalers, healthcare buyers, and commercial partners, with a revenue-sharing model available for successful introductions.
Mavencorp Capital continues to back founders building infrastructure that matters, in healthcare, in technology, and at the intersection of both.